St. Jude wins European approval for cardiac ablation system

June 17, 2010 by MedCity News

St. Jude Medical Inc. lands European regulatory approval for a cardiac ablation system used to correct arrhythmias.

MedCity News logo

By Brandon Glenn

St. Jude Medical Inc. (NYSE:STJ) received European regulatory approval for a cardiac ablation system used in procedures to destroy diseased tissue in patients with abnormal heart rhythms.

Receiving the CE Mark means that St. Jude may beginning marketing and selling its EnSite Contact Technology platform in the Eurpean Union. The system has not been cleared for U.S. sales.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp